Rule of Carbone Monoxyde in the Ex Vivo Lung Perfusion Reconditionning
Primary Purpose
Neurogenic Lung Edema
Status
Unknown status
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Carbone monoxide
Sponsored by
About this trial
This is an interventional prevention trial for Neurogenic Lung Edema
Eligibility Criteria
Inclusion Criteria:
Lung Edema
Exclusion Criteria:
Infection Severe Emphysema Tumor
Sites / Locations
- CHU Mont-Godinne
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
Ex vivo without CO
EX Vivo with carbone monoxide
Arm Description
During the Ex Vivo Lung Perfusion reconditioning,the lungs will be ventilated wit h Oxygen (21%) and Carbon Monoxide (250ppm).
Outcomes
Primary Outcome Measures
Incidence on Primary Graft Dysfunction
Secondary Outcome Measures
Full Information
NCT ID
NCT02032082
First Posted
January 8, 2014
Last Updated
March 13, 2016
Sponsor
University Hospital of Mont-Godinne
1. Study Identification
Unique Protocol Identification Number
NCT02032082
Brief Title
Rule of Carbone Monoxyde in the Ex Vivo Lung Perfusion Reconditionning
Study Type
Interventional
2. Study Status
Record Verification Date
March 2016
Overall Recruitment Status
Unknown status
Study Start Date
January 2014 (undefined)
Primary Completion Date
January 2018 (Anticipated)
Study Completion Date
January 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital of Mont-Godinne
4. Oversight
5. Study Description
Brief Summary
Ex vivo lung perfusion (EVLP) is not a new concept and has been widely used to study lung function in small animals. It also has been shown to be a useful technique to evaluate lungs from donation after cardiac death (DCD) (Yeung, Thorac Surg Clin, 2009). It has been recently demonstrated successful application of an acellular EVLP technique in optimalizing lung function ex vivo for an extended period of time. Following 12 h of normothermic EVLP, patients were transplanted and demonstrated immediate life-sustaining function with promising short-term evolution (Aigner, Am J Transplant, 2012; Sanchez, J Heart Lung Transplant, 2012; Cypel, N Engl J Med, 2011).
Lung donation obtained after carbon monoxide intoxication has been recognized as excellent organs because of less general inflammation and less primary graft dysfunction after procedure. In a murine model of brain dead, carbon monoxide inhalation at a low concentration (50 to 500 parts per million (ppm)) exerts significant cytoprotection in several lung injury models via its vasodilatation, anti-inflammatory, and anti-apoptotic properties (Dong, J Heart Lung transplant, 2010). The carbon monoxide inhalation down-regulates pro-inflammatory cytokines (TNF-alpha, IL-6) along with the increase of anti-inflammatory cytokine (IL-10) in recipient serum. The inhalation significantly decreases cell apoptosis in lung grafts, inhibiting mRNA and protein expression of intercellular adhesion molecule-1 (ICAM-1) and caspase-3 in lung grafts (Zhou, Chin Med J, 2008).
Apoptotis and inflammatory processes may, in part, concern alveolar tissue. Research in the field of biomarkers is now opening new perspectives with the development of non-invasive tests allowing for monitoring inflammation and damage in the deep lung. Blood tests (Bernard, Toxicol Appl Pharmacol, 2005) measuring lung-specific proteins (pneumoproteins) such as Clara cell protein (CC16) and surfactant-associated proteins (A, B or D) are now available to evaluate the permeability and/or the cellular integrity of the pulmonary epithelium. These dosages may constitute an interesting way for monitoring the quality of the lung before implantation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neurogenic Lung Edema
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ex vivo without CO
Arm Type
No Intervention
Arm Title
EX Vivo with carbone monoxide
Arm Type
Experimental
Arm Description
During the Ex Vivo Lung Perfusion reconditioning,the lungs will be ventilated wit h Oxygen (21%) and Carbon Monoxide (250ppm).
Intervention Type
Other
Intervention Name(s)
Carbone monoxide
Primary Outcome Measure Information:
Title
Incidence on Primary Graft Dysfunction
Time Frame
Up to 2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Lung Edema
Exclusion Criteria:
Infection Severe Emphysema Tumor
Facility Information:
Facility Name
CHU Mont-Godinne
City
Yvoir
State/Province
Namur
ZIP/Postal Code
5530
Country
Belgium
12. IPD Sharing Statement
Learn more about this trial
Rule of Carbone Monoxyde in the Ex Vivo Lung Perfusion Reconditionning
We'll reach out to this number within 24 hrs